Log in or Sign up for Free to view tailored content for your specialty!
Skin Disorders News
Regeneron, Sanofi begin phase 3 dupilumab trial for adults with AD
Regeneron Pharmaceuticals and Sanofi have announced the start of a phase 3 clinical trial of dupilumab in adults with moderate-to-severe atopic dermatitis not adequately controlled with topical medications, according to a press release.
SLIT effectively treated dust mite-sensitized children with AD
Sublingual immunotherapy with a standardized house dust mite extract was more effective in treating children with atopic dermatitis and house dust mite sensitization compared with standard treatment, according to recent study results.
Log in or Sign up for Free to view tailored content for your specialty!
Emollient effectively prevented atopic dermatitis in infants
Emollient therapy from birth was an effective method of preventing atopic dermatitis in infants, according to recent study results.
More diversified, randomized controlled trials of atopic dermatitis treatment needed
A need exists for large-scale, randomized, controlled trials of systemic treatment for atopic dermatitis that include more racial and ethnic diversity to better represent the diverse U.S. population, according to a literature review.
Skin barrier dysfunction, earlier introduction of food allergens among EAACI meeting topics
Research on predicting and possibly reducing food allergies in infancy was presented at the Food Allergy and Anaphylaxis Meeting, organized by the European Academy of Allergy and Clinical Immunology, in Dublin.
Vitamin D supplementation improved winter AD in children
Vitamin D supplementation was effective in treating winter-related atopic dermatitis in Mongolian children who were at high risk for vitamin D deficiency when compared with placebo in a recent study.
Angioedema deaths in US uncommon
Angioedema-related mortality in the United States from 1979 to 2010 was rare, with hereditary angioedema deaths decreasing and nonhereditary angioedema deaths increasing, according to recent study results.
Merck sells Claritin, Afrin rights to Bayer AG
Merck announced in a press release it has completed the sale of its consumer care business, which includes its allergy-treatment products Claritin and Afrin, to Bayer AG.
Sanofi, Regeneron: Dupilumab effective in patients with chronic sinusitis, nasal polyps
Sanofi and Regeneron Pharmaceuticals announced that a phase 2a study of dupilumab met all endpoints in patients with chronic sinusitis with nasal polyps who did not respond to intranasal corticosteroids, according to a press release.
No known factor predictive of chronic urticaria remission in children
Researchers found that although children with chronic urticaria typically have positive outcomes, there is no one factor that can significantly predict remission.